Acumen Pharmaceuticals, Inc.

ABOS · NASDAQ

Acumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.

Follow Add to Watchlist Ask Question

NASDAQ ABOS Coverage Bootstrap Biotechnology Alzheimer Disease Clinical-Stage Biotech

Latest ReportMay 13, 2026Acumen Pharmaceuticals (ABOS): the Alzheimer readout racing a cash clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.